ALVR
Allovir Inc
Price:  
9.81 
USD
Volume:  
9,429.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

Allovir WACC - Weighted Average Cost of Capital

The WACC of Allovir Inc (ALVR) is 10.5%.

The Cost of Equity of Allovir Inc (ALVR) is 15.95%.
The Cost of Debt of Allovir Inc (ALVR) is 5.00%.

Range Selected
Cost of equity 12.60% - 19.30% 15.95%
Tax rate -% - 0.10% 0.05%
Cost of debt 5.00% - 5.00% 5.00%
WACC 8.8% - 12.2% 10.5%
WACC

Allovir WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 1.9 2.58
Additional risk adjustments 0.0% 0.5%
Cost of equity 12.60% 19.30%
Tax rate -% 0.10%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 8.8% 12.2%
Selected WACC 10.5%

Allovir's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for Allovir:

cost_of_equity (15.95%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (1.9) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.